| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2007 | 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling | Su R.-Y.; Chao Y.; Chen T.-Y.; Huang D.-Y.; WAN-WAN LIN | Molecular Cancer Therapeutics | 88 | 84 | |
| 2021 | Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells | KENG-HSUEH LAN ; Tsai C.-L.; Chen Y.-Y.; Lee T.-L.; Pai C.-W.; Chao Y.; Lan K.-L. | Biochemical and Biophysical Research Communications | 1 | 1 | |
| 2007 | The anti-inflammatory actions of LCY-2-CHO, a carbazole analogue, in vascular smooth muscle cells | Ho F.-M.; Kang H.-C.; Lee S.-T.; Chao Y.; Chen Y.-C.; Huang L.-J.; WAN-WAN LIN | Biochemical Pharmacology | 44 | 42 | |
| 2022 | Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study | Chen S.-C.; Huang Y.-H.; Chen M.-H.; Hung Y.-P.; Lee R.-C.; YU-YUN SHAO ; Chao Y. | BMC Cancer | 8 | 6 | |
| 2020 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU ; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU ; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. | The Lancet Oncology | 280 | 256 | |
| 2002 | Aurintricarboxylic acid protects against cell death caused by lipopolysaccharide in macrophages by decreasing inducible nitric-oxide synthase induction via IκB kinase, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase inhibition | Tsi C.-J.; Chao Y.; Chen C.-W.; WAN-WAN LIN | Molecular Pharmacology | 42 | 41 | |
| 2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 2 | 1 | |
| 2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 590 | 574 | |
| 2005 | Cell apoptosis induced by a synthetic carbazole compound LCY-2-CHO is mediated through activation of caspase and mitochondrial pathways | Hsu M.-J.; Chao Y.; Chang Y.-H.; Ho F.-M.; Huang L.-J.; Huang Y.-L.; TIEN-YAU LUH ; Chen C.-P.; WAN-WAN LIN | Biochemical Pharmacology | 24 | 22 | |
| 2013 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) | Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG | Liver International | 62 | 56 | |
| 2019 | Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
| 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 42 | 42 | |
| 2022 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study | Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. | Gastric Cancer | 4 | 5 | |
| 2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. | Gastric Cancer | 35 | 35 | |
| 2016 | Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer | Chiang N.-J.; CHIUN HSU ; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. | Scientific Reports | 16 | 14 | |
| 2021 | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 | Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG ; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. | Cancer | 13 | 15 | |
| 2015 | High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms | Chen M.-H.; Kuo Y.-J.; Yeh Y.-C.; Lin Y.-C.; Tzeng C.-H.; Liu C.-Y.; Chang P.M.H.; Chen M.-H.; YUNG-MING JENG ; Chao Y. | Journal of the Chinese Medical Association | 26 | 21 | |
| 2019 | Hotspot analysis and improvement schemes for capacitive deionization (CDI) using life cycle assessment | Shiu H.-Y.; Lee M.; Chao Y.; Chang K.-C.; Hou C.-H.; PEI-TE CHIUEH ; CHIA-HUNG HOU | Desalination | 16 | 15 | |
| 2002 | Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid | Chen C.-W.; Chao Y.; Chang Y.-H.; Hsu M.-J.; WAN-WAN LIN | British Journal of Pharmacology | 34 | 36 | |
| 2015 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Chen J.S.; CHIH-HUNG HSU ; Chiang N.J.; Tsai C.S.; Tsou H.H.; Huang S.F.; Bai L.Y.; Chang I.C.; Shiah H.S.; Ho C.L.; Yen C.J.; Lee K.D.; Chiu C.F.; Rau K.M.; Yu M.S.; Yang Y.; Hsieh R.K.; Chang J.Y.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Wei T.-C.; on behalf of the Taiwan Cooperative Oncology Group | Annals of Oncology | 121 | 109 |
